Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Search Results

Filter
  • 1-10 of  19,674 results for ""HISTONE deacetylase inhibitors""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.

  • Authors : Liu M; Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P. R. China.; Gao S

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology

  • Source: Journal of medicinal chemistry [J Med Chem] 2022 Sep 22; Vol. 65 (18), pp. 12200-12218. Date of Electronic Publication: 2022 Sep 12.Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer.

  • Authors : Knoche SM; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.; Brumfield GL

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/therapeutic use ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapyPancreatic Carcinoma

  • Source: PloS one [PLoS One] 2022 Sep 20; Vol. 17 (9), pp. e0273518. Date of Electronic Publication: 2022 Sep 20 (Print Publication: 2022).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.

  • Authors : Sun Z; School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.; Deng B

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/chemistry ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Histone Deacetylases*/Histone Deacetylases*/Histone Deacetylases*/metabolism

  • Source: European journal of medicinal chemistry [Eur J Med Chem] 2022 Sep 05; Vol. 239, pp. 114544. Date of Electronic Publication: 2022 Jun 21.Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Histone deacetylase inhibitor use as a radiosensitizer in solid organ malignancies: a systematic review protocol.

  • Authors : Sullivan J; School of Medicine, Flinders University, Adelaide, SA, Australia.; Feng Z

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/therapeutic use ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy

  • Source: JBI evidence synthesis [JBI Evid Synth] 2022 Sep 01; Vol. 20 (9), pp. 2378-2386. Date of Electronic Publication: 2022 Sep 01.Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 101764819 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.

  • Authors : Zhang K; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/therapeutic use ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy

  • Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2022 Sep 01; Vol. 71, pp. 128825. Date of Electronic Publication: 2022 May 27.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Differential molecular mechanistic behavior of HDACs in cancer progression.

  • Authors : Singh T; Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, 151401, India.; Kaur P

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/therapeutic use ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy

  • Source: Medical oncology (Northwood, London, England) [Med Oncol] 2022 Aug 16; Vol. 39 (11), pp. 171. Date of Electronic Publication: 2022 Aug 16.Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X

Record details

×
Academic Journal

Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.

  • Authors : Yue K; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.; Qin M

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/chemistry ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Histone Deacetylases*/Histone Deacetylases*/Histone Deacetylases*/metabolism

  • Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2022 Aug 15; Vol. 70, pp. 128797. Date of Electronic Publication: 2022 May 14.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.

  • Authors : Federico S; Department of Biotechnology, Chemistry and Pharmacy, DoE Department of Excellence 2018-2022, University of Siena, 53100, Siena, Italy.; Khan T

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/chemistry ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Hydroxamic Acids*/Hydroxamic Acids*/Hydroxamic Acids*/chemistry

  • Source: European journal of medicinal chemistry [Eur J Med Chem] 2022 Aug 05; Vol. 238, pp. 114409. Date of Electronic Publication: 2022 May 01.Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/therapeutic use ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy

  • Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Aug 02; Vol. 28 (15), pp. 3367-3377.Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265

Record details

×
Academic Journal

Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.

  • Authors : Kee HJ; Heart Research Center of Chonnam National University Hospital, Gwangju 61469, Republic of Korea; Hypertension Heart Failure Research Center, Chonnam National University Hospital, Gwangju 61469, Republic of Korea. Electronic address: .

Subjects: Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/pharmacology ; Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/Histone Deacetylase Inhibitors*/therapeutic use ; Hypertension*/Hypertension*/Hypertension*/drug therapy

  • Source: Biochemical pharmacology [Biochem Pharmacol] 2022 Aug; Vol. 202, pp. 115111. Date of Electronic Publication: 2022 May 28.Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  19,674 results for ""HISTONE deacetylase inhibitors""